SCHEMBL31356845

SCHEMBL31356845

COc1ccc2c(=O)c3c([nH]c2c1)CC(C1CCC1)CC3=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.45
▸ PIM1 P11309 4/20 0.44
▸ CLK4 Q9HAZ1 3/20 0.44
▸ AXL P30530 1/20 0.44
▸ PTK2B Q14289 1/20 0.44
▸ MAPKAPK5 Q8IW41 1/20 0.44
▸ SRPK1 Q96SB4 1/20 0.44
▸ ERBB2 P04626 1/20 0.42
▸ FLT3 P36888 1/20 0.42
▸ CSNK1G1 Q9HCP0 1/20 0.42
▸ CDK4 P11802 2/20 0.41
▸ CCND1 P24385 2/20 0.41
▸ ADRA2A P08913 1/20 0.40
▸ ADRA2B P18089 1/20 0.40
▸ ADRA2C P18825 1/20 0.40
▸ HTR7 P34969 1/20 0.40
▸ NISCH Q9Y2I1 1/20 0.40
▸ KDR P35968 1/20 0.40
▸ TP53 P04637 2/20 0.39
▸ ALDH1A1 P00352 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31356752 0.98 PIM1 (0.44) KDM4EPIM1CLK4AXLPTK2B
SCHEMBL31356853 0.97 PIM1 (0.43) KDM4EPIM1CLK4AXLPTK2B
SCHEMBL31356870 0.95 PIM1 (0.46) KDM4EPIM1CLK4AXLPTK2B
SCHEMBL31356815 0.90 PIM1 (0.42) KDM4EPIM1CLK4AXLPTK2B
SCHEMBL31356833 0.86 ABCG2 (0.48) KDM4ECLK4KDRALDH1A1HPGD
SCHEMBL31356665 0.84 PIM1 (0.46) KDM4EPIM1CLK4AXLPTK2B
SCHEMBL31356848 0.82 PIM1 (0.46) PIM1CLK4AXLPTK2BMAPKAPK5
SCHEMBL31356838 0.81 PIM1 (0.46) PIM1CLK4AXLPTK2BMAPKAPK5
SCHEMBL31356817 0.79 PIM1 (0.48) KDM4EPIM1CLK4AXLPTK2B
SCHEMBL31356773 0.79 KDM4E (0.46) KDM4EPIM1CLK4AXLPTK2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4727923-A1 TETRAHYDROACRIDINONE ANALOGUES FOR TREATMENT AND PREVENTION OF MALARIA University of Georgia Research Foundation, Inc. (US) 2026-04-22 — — EP disclosed
US-20260098012-A1 TETRAHYDROACRIDINONE ANALOGUES FOR TREATMENT AND PREVENTION OF MALARIA UNIV GEORGIA (US) 2026-04-09 — — US disclosed
WO-2024258904-A1 TETRAHYDROACRIDINONE ANALOGUES FOR TREATMENT AND PREVENTION OF MALARIA UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2024-12-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260098012-A1 TETRAHYDROACRIDINONE ANALOGUES FOR TREATMENT AND PREVENTION OF MALARIA CD47, SLC11A2, G6PD KDM4E 1264/4885PIM1 351/4885CLK4 1981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback